TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Equities research analysts at HC Wainwright dropped their Q3 2024 earnings estimates for TransCode Therapeutics in a report issued on Thursday, August 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.51) per share for the quarter, down from their prior estimate of ($0.35). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($1.98) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($2.05) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.30) EPS and FY2028 earnings at ($0.25) EPS.
TransCode Therapeutics Stock Performance
NASDAQ:RNAZ opened at $0.28 on Monday. TransCode Therapeutics has a one year low of $0.22 and a one year high of $128.00. The business has a fifty day moving average price of $0.67 and a 200-day moving average price of $0.78.
Institutional Inflows and Outflows
About TransCode Therapeutics
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Recommended Stories
- Five stocks we like better than TransCode Therapeutics
- Learn Technical Analysis Skills to Master the Stock Market
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Breakout Stocks: What They Are and How to Identify Them
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.